Results 161 to 170 of about 216,339 (397)

The role of cytokines in ovarian cancer drug resistance

International Journal of Cancer, EarlyView.
Abstract Ovarian cancer is the leading cause of death among women diagnosed with female reproductive system cancers. While significant advances have been made in treating various types of cancer, progress in ovarian cancer treatment over the past 20 years has been minimal, and the treatment course of ovarian cancer is not linear. Although many patients
Lu Wang, Yunxia Zang, Rebeka Dejenie, Junyuan Bing, Shixia Dong, Yanfei Zhang, Yi Zhu, Jingjing Li   +7 more
wiley   +1 more source

Bevacizumab for the Treatment of Recurrent Glioblastoma

Clinical Medicine Insights: Oncology, 2011
Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death.
Marc C. Chamberlain
doaj   +1 more source

Bevacizumab for Retinopathy of Prematurity [PDF]

New England Journal of Medicine, 2011
Anna L. Ells, Jayne E Camuglia, Glen A. Gole   +2 more
openaire   +8 more sources

Salvage Fractionated Stereotactic Re-irradiation (FSRT) for Patients with Recurrent High Grade Gliomas Progressed after Bevacizumab Treatment [PDF]

, 2017
Purpose/Objectives: Bevacizumab failure is a major clinical problem in the manage- ment of high grade gliomas (HGG), with a median overall survival of less than 4 months (m).
Andrews MD, David W., Bar-Ad, Voichita, Bhamidipati, Deepak, Blomain, Erik S, Dan, Tu, Evans, James J., Farrell, MD, Christopher J, Glass, MD, Jon, Judy, MD, Kevin, Kim, Lyndon, Palmer, Joshua, Shi, Wenyin, Siglin, Joshua, Wang, Yang, Werner-Wasik, Maria   +14 more
core   +2 more sources

Novel therapeutic strategy targeting STMN1 using chlorambucil‐conjugated pyrrole–imidazole polyamide in small cell lung cancer

International Journal of Cancer, EarlyView.
What's New? Small cell lung cancer (SCLC) is aggressive and difficult to treat but exhibits high levels of stathmin 1 (STMN1), a candidate therapeutic target. In this study, the authors synthesized a chlorambucil (Chb)‐conjugated pyrrole–imidazole polyamide (PIP) compound targeting the STMN1 promoter and DNA sequences and evaluated its efficacy in ...
Ryohei Yoshikawa, Takayoshi Watanabe, Yoichi Ohtaki, Toshikazu Bando, Hiroshi Sugiyama, Takuya Araki, Hideaki Yashima, Bilguun Erkhem‐Ochir, Haruka Okami, Gendensuren Dorjkhorloo, Ikuma Shioi, Toshiteru Nagashima, Natsuko Kawatani, Tomohiro Yazawa, Eiji Narusawa, Takayuki Kosaka, Osamu Kawashima, Mitsuhiro Kamiyoshihara, John D. Minna, Luc Girard, Ken Shirabe, Hiroki Nagase, Kimihiro Shimizu, Takehiko Yokobori   +23 more
wiley   +1 more source

Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity

Therapeutic Advances in Medical Oncology, 2010
The addition of bevacizumab to currently available treatment options for metastatic colorectal cancer has changed the traditional chemotherapy-based paradigm.
G. Chong, N.C. Tebbutt
doaj   +1 more source

Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab [PDF]

, 2004
Nishan H. Fernando, Herbert I. Hurwitz
openalex   +1 more source

Targeting the ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) as a potential therapeutic strategy to overcome anti‐VEGF resistance in endometrial cancer

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To investigate the role of ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) in endometrial cancer (EC) progression and its potential as a therapeutic target to enhance the efficacy of antiangiogenic treatment. Methods ST3Gal1 expression and its clinical relevance were analyzed in EC tissues.
Chia‐Hao Liu, Szu‐Ting Yang, Wei‐Ting Chao, Chen‐Hao Lin, Yu‐Chieh Lee, Chiung‐Ru Lai, Shie‐Liang Hsieh, Liang‐Wei Wang, Peng‐Hui Wang   +8 more
wiley   +1 more source

Reply to “PET concerns in bevacizumab treatment” [PDF]

, 2004
Christopher G. Willett, D. G. Duda, Alan J. Fischman, Rakesh K. Jain   +3 more
openalex   +1 more source

Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To compare overall survival (OS) in patients with high‐grade serous ovarian cancer (HGSOC) treated with intraperitoneal (IP) chemotherapy versus intravenous (IV) chemotherapy. Methods A retrospective study of Stage III HGSOC with optimal primary cytoreduction during 2007–2019, followed by adjuvant IP or IV chemotherapy.
Joshua S Cheruvathur, Gabriel Levin, Reitan Ribeiro, Florentin Racovitan, Joanne Power, Xing Zeng, John Sampalis, Lucy Gilbert   +7 more
wiley   +1 more source